UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - RA PHARMACEUTICALS INC ownership

RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 62 filers reported holding RA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ownership history of RA PHARMACEUTICALS INC
ValueSharesWeighting
Q1 2020$1,971,627,000
-79.1%
41,067
-79.6%
0.00%
-83.3%
Q4 2019$9,435,747,000
+26.9%
201,060
-36.1%
0.01%
+20.0%
Q3 2019$7,436,908,000
-22.3%
314,457
-1.2%
0.01%
-28.6%
Q2 2019$9,571,582,000
+35.7%
318,310
+1.1%
0.01%
+40.0%
Q1 2019$7,052,237,000
+6442.4%
314,832
+1450.9%
0.01%
Q1 2018$107,793,00020,3000.00%
Other shareholders
RA PHARMACEUTICALS INC shareholders Q2 2018
NameSharesValueWeighting ↓
RA Capital Management 3,851,808$20,453,0001.57%
NEA Management Company, LLC 5,493,636$29,171,0001.30%
Foresite Capital Management IV, LLC 450,000$2,390,0000.99%
Novo Holdings A/S 1,465,838$7,784,0000.98%
Consonance Capital Management LP 1,454,761$7,725,0000.71%
VHCP Management II, LLC 544,612$2,892,0000.70%
ACUTA CAPITAL PARTNERS, LLC 270,000$1,434,0000.23%
Athanor Capital, LP 67,150$357,0000.16%
Rock Springs Capital Management LP 600,000$3,186,0000.14%
Eventide Asset Management 388,000$2,060,0000.10%
View complete list of RA PHARMACEUTICALS INC shareholders